Research Topics
| E NutescuSummaryAffiliation: University of Illinois at Chicago Country: USA Publications
| Collaborators
|
Detail Information
Publications
The future of anticoagulation clinicsEdith A Nutescu
College of Pharmacy, Department of Pharmacy Practice, The University of Illinois at Chicago, Chicago, IL 60612, USA
J Thromb Thrombolysis 16:61-3. 2003..Comprehensive Antithrombosis Centers (CAC) will most likely manage patients with thrombotic disorders treated with a range of anticoagulant therapies...- Strategies for cost-effective prevention and treatment of venous thromboembolism. IntroductionEdith A Nutescu
The University of Illinois at Chicago, College of Pharmacy, 833 S. Wood St, MC 886, Room 164, Chicago, IL 60612, USA
Am J Health Syst Pharm 61:S3-4. 2004 - Emerging options in the treatment of venous thromboembolismEdith A Nutescu
The University of Illinois at Chicago, College of Pharmacy, 833 S Wood St, MC 886, Room 164, Chicago, IL 60612, USA
Am J Health Syst Pharm 61:S12-7. 2004.... - Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation managementEdith A Nutescu
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA
Pharmacotherapy 24:199S-202S. 2004..Traditional anticoagulation monitoring services will have to retool for the future if they are to remain relevant in the new era of novel antithrombotic.agents... - ASHP therapeutic position statement on antithrombotic therapy in chronic atrial fibrillationEdith A Nutescu
University of Illinois at Chicago College of Pharmacy, 833 South Wood Street, M/C 886, Room 164, Chicago, IL 60612, USA
Am J Health Syst Pharm 64:2281-91. 2007 - Point of care monitors for oral anticoagulant therapyEdith A Nutescu
Department of Pharmacy Practice, College of Pharmacy, The University of Illinois at Chicago, 60612, USA
Semin Thromb Hemost 30:697-702. 2004..Because technology differs among the various devices, accuracy and precision need to be determined for individual devices. The various devices cannot be used interchangeably, and individual device performance cannot be generalized... - A pharmacologic overview of current and emerging anticoagulantsEdith A Nutescu
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 60612, USA
Cleve Clin J Med 72:S2-6. 2005..Because of their convenience and ease of use, some of these novel compounds are competing with the traditional anticoagulants and are needed additions to the antithrombotic arsenal... - Assessing, preventing, and treating venous thromboembolism: evidence-based approachesEdith A Nutescu
University of Illinois at Chicago, Department of Pharmacy Practice, Chicago, IL 60612, USA
Am J Health Syst Pharm 64:S5-13. 2007.... - Easing the economic burden of acute coronary syndromes: cost-effectiveness of emerging therapiesEdith A Nutescu
Department of Pharmacy Practice, University of Illinois at Chicago, 833 S Wood St, Rm 164, MC886, Chicago, IL 60612, USA
Am J Manag Care 12:S444-50. 2006..Health economic analysis of fondaparinux treatment is currently limited to VTE scenarios but point to a cost benefit associated with fondaparinux compared with enoxaparin... - New anticoagulant agents: direct thrombin inhibitorsEdith A Nutescu
Department of Pharmacy Practice, Antithrombosis Center, University of Illinois at Chicago, College of Pharmacy and Medical Center, IL 60612, USA
Clin Geriatr Med 22:33-56, viii. 2006.... - Anticoagulant agents are mainstay therapies in the prevention and treatment of arterial and venous thrombosis. IntroductionEdith A Nutescu
Department of Pharmacy Practice, University of Illinois at Chicago, 833 S Wood St, Rm 164, MC886, Chicago, IL 60612, USA
Am J Manag Care 12:S427-9. 2006 - Drug evaluation: the directly activated Factor Xa inhibitor otamixabanEdith A Nutescu
Antithrombosis Center, Department of Pharmacy Practice, College of Pharmacy, The University of Illinois at Chicago, Chicago, IL 60612 7230, USA
IDrugs 9:854-65. 2006..Otamixaban is a promising agent that merits further consideration for clinical trials in patients with coronary thrombosis... - Warfarin and its interactions with foods, herbs and other dietary supplementsEdith A Nutescu
Department of Pharmacy Practice, University of Illinois, College of Pharmacy, Chicago, IL 60612, USA
Expert Opin Drug Saf 5:433-51. 2006..Practical steps for patients and providers to minimise these interactions are highlighted... - New blood thinner offers first potential alternative in 50 years: ximelagatranEdith A Nutescu
Antithrombosis Service, Department of Pharmacy Practice, College of Pharmacy, The University of Illinois at Chicago, 60612, USA
J Cardiovasc Nurs 19:374-83. 2004..Pending regulatory approval, ximelagatran may help overcome barriers to appropriate anticoagulant therapy, thereby decreasing morbidity and mortality associated with thrombotic diseases... - Choosing the appropriate antithrombotic agent for the prevention and treatment of VTE: a case-based approachEdith A Nutescu
Antithrombosis Center, Department of Pharmacy Practice, College of Pharmacy, The University of Illinois at Chicago, Chicago, IL 60612 7230, USA
Ann Pharmacother 40:1558-71. 2006..To review the risk of venous thromboembolism (VTE) in various patient populations and evaluate the agents available for the prevention and treatment of VTE using a case-based approach... - Traditional versus modern anticoagulant strategies: summary of the literatureEdith Nutescu
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, M C 886, Chicago, IL 60612, USA
Am J Health Syst Pharm 59:S7-14. 2002..Primary studies of new agents, including oral direct thrombin inhibitors and synthetic pentasaccharides for the treatment of ACS are promising; however, more data are needed on their safety and efficacy... - Characteristics of novel anticoagulants and potential economic implicationsEdith Nutescu
Antithrombosis Center, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
Am J Manag Care 17:S27-32. 2011..This article will review the characteristics of the new oral anticoagulants, which may potentially translate into cost savings for the healthcare system... - Ezetimibe: a selective cholesterol absorption inhibitorEdith A Nutescu
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA
Pharmacotherapy 23:1463-74. 2003..In combination therapy with a statin, ezetimibe is used in patients who cannot tolerate high statin doses or in those who need additional LDL reductions despite maximum statin doses... - Drug and dietary interactions of warfarin and novel oral anticoagulants: an updateEdith Nutescu
Department of Pharmacy Practice and Center for Pharmacoeconomic Research, University of Illinois at Chicago, College of Pharmacy, 833 S Wood St MC 886, Rm 164, Chicago, IL 60612, USA
J Thromb Thrombolysis 31:326-43. 2011..The objective of this paper is to give an update on drug and dietary interactions with warfarin and the novel oral anticoagulants, dabigatran, rivaroxaban, apixaban, and edoxaban... - Tinzaparin: considerations for use in clinical practiceEdith A Nutescu
Department of Pharmacy Practice, College of Pharmacy, The University of Illinois at Chicago, Chicago, IL, USA
Ann Pharmacother 37:1831-40. 2003..To evaluate the safety and effectiveness of tinzaparin for the prevention and treatment of venous thromboembolism (VTE)... - Direct thrombin inhibitors for anticoagulationEdith A Nutescu
Antithrombosis Service, College of Pharmacy, The University of Illinois at Chicago, Chicago, IL 60612, USA
Ann Pharmacother 38:99-109. 2004..To review the progress in developing direct thrombin inhibitors (DTIs) for anticoagulation within the context of existing anticoagulation therapies... - Basic terminology in obtaining reimbursement for pharmacists' cognitive servicesEdith A Nutescu
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
Am J Health Syst Pharm 64:186-92. 2007..A basic overview and definitions of commonly used billing and reimbursement terminology that pharmacists will need to know to obtain reimbursement for cognitive services are provided... - Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settingsEdith A Nutescu
Antithrombosis Center, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, IL 60612, USA
Ann Pharmacother 43:1064-83. 2009..To develop practical recommendations for the use of low-molecular-weight heparins (LMWHs) as prophylaxis and treatment of venous thromboembolism and acute coronary syndromes in patients with impaired renal function or obesity... - Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndromeEdith A Nutescu
Antithrombosis Center, The University of Illinois at Chicago, College of Pharmacy, Department of Pharmacy Practice, 833 S Wood Street, MC 886, Room 164, Chicago, Illinois 60612 7230, USA
Expert Opin Pharmacother 9:95-105. 2008..Based on published economic analyses, the incremental drug costs of LMWH compared with UFH are compensated for by savings in medical-resource costs secondary to reducing ischemic events in NSTE-ACS patients... - New anticoagulant agents: direct thrombin inhibitorsEdith A Nutescu
Department of Pharmacy Practice, Antithrombosis Center, University of Illinois at Chicago, College of Pharmacy and Medical Center, 833 South Wood Street, M C 886, Room 164, Chicago, IL 60612, USA
Cardiol Clin 26:169-87, v-vi. 2008.... - Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitorsEdith A Nutescu
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA
Pharmacotherapy 24:82S-87S. 2004..Fondaparinux is a welcomed addition to the available antithrombotic options... - Treatment of venous thromboembolism: challenging the unfractionated heparin standardEdith Nutescu
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA
Pharmacotherapy 24:127S-131S. 2004..As clinical data regarding these new agents for treatment of VTE continue to evolve, their role in clinical practice will be elucidated... - Anticoagulation patient self-monitoring in the United States: considerations for clinical practice adoptionEdith A Nutescu
Department of Pharmacy Practice and Pharmacy Administration, University of Illinois at Chicago, Chicago, Illinois 60612 7230, USA
Pharmacotherapy 31:1161-74. 2011..Further studies are needed to explore factors that influence the adoption of self-monitoring in the United States and to evaluate the feasibility and implementation in real-life clinical settings... - Survey of hospitals for guidelines, policies, and protocols for anticoagulantsVikrant Vats
Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
Am J Health Syst Pharm 64:1203-8. 2007.... - Oral anticoagulation: preparing for changeEdith A Nutescu
University of Illinois at Chicago, College of Pharmacy, Chicago, Illinois, USA
J Am Med Dir Assoc 5:2-11. 2004..Further, the results of clinical trials suggest that ximelagatran may be as effective as warfarin in preventing stroke and VTE... - Examining differences in weekly warfarin dose in patients with and without cancerKaren M Grogan
College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
Ther Drug Monit 29:638-43. 2007.... - Sex difference in the antiplatelet effect of aspirin in patients with strokeLarisa H Cavallari
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612 7230, USA
Ann Pharmacother 40:812-7. 2006..The factors contributing to this variability are not well defined... - Predictors of unstable anticoagulation in African AmericansLarisa H Cavallari
Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, 833 S Wood St, Room 164, Chicago, IL 60612 7230, USA
J Thromb Thrombolysis 27:430-7. 2009..We sought to identify contributors to unstable anticoagulation in African Americans... - Impact of prescribing guidelines for inpatient anticoagulationGlen T Schumock
Center for Pharmacoeconomic Research, Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA
Ann Pharmacother 38:1570-5. 2004..As such, these drugs may be amenable to the use of prescribing guidelines. However, relatively little has been published on the effect of such guidelines on clinical outcomes or costs of care... - Survey of hospital policies regarding low-molecular-weight heparinsGlen T Schumock
Department of Pharmacy Practice, University of Illinois at Chicago, 833 S Wood Street M C 886, Chicago, IL 60612, USA
Am J Health Syst Pharm 59:534-8. 2002..Policies to promote alternatives to LMWHs were reported by 18% of the respondents. A multihospital survey showed that many hospitals wanted but relatively few had prescribing guidelines for LMWHs... - Hospital guidelines for use of low-molecular-weight heparinsEdith A Nutescu
Antithrombosis Services, University of Illinois at Chicago, Chicago, IL, USA
Ann Pharmacother 37:1072-81. 2003..CONCLUSIONS: The process by which these guidelines were developed, plus the final set of guidelines, may be useful to hospitals and healthcare systems contemplating or engaged in a similar effort with this class of drugs... - Factors that influence prescribing decisionsGlen T Schumock
Center for Pharmacoeconomic Research, and Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612 7230, USA
Ann Pharmacother 38:557-62. 2004..Knowledge of these differences could have importance in predicting the effectiveness of strategies designed to influence drug use in this setting... - Factors that influence prescribing within a therapeutic drug classEdith A Nutescu
Antithrombosis Services, University of Illinois, Chicago, IL, USA
J Eval Clin Pract 11:357-65. 2005..This information may be of value in designing programs to alter medication use... - Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgeryEdith A Nutescu
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA
Ann Pharmacother 42:1216-21. 2008..Recently published orthopedic guidelines have focused on prevention of pulmonary embolism as a primary outcome, but deep vein thrombosis (DVT) occurrence should not be readily dismissed... - Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic populationBeth Nochowitz
Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, USA
Ann Pharmacother 43:1165-72. 2009..Poor adherence to warfarin therapy is a major contributor to subtherapeutic anticoagulation... - Impact of oral direct thrombin inhibitors on anticoagulation clinicsEdith A Nutescu
Department of Pharmacy Practice, University of Illinois at Chicago, IL 60612, USA
Pharmacotherapy 24:1204-12. 2004..Clinics that are proactive and redesign their patient care services to consider emerging anticoagulant agents will be more likely to remain relevant and viable... - Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for strokeKathryn M Momary
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Ill, USA
Cerebrovasc Dis 27:585-93. 2009..We sought to determine whether cyclooxygenase-1 (PTGS1) genotype is associated with the ability of aspirin to inhibit platelet aggregation in patients at risk for stroke... - Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiativeMichael B Bottorff
College of Pharmacy, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
Pharmacotherapy 27:1145-62. 2007..The role of the pharmacist is pivotal in ensuring adherence to clinical guidelines by interacting with both the physician and patient... - Antithrombotic therapy for the treatment of venous thromboembolismEdith A Nutescu
Department of Pharmacy Practice, The University of Illinois at Chicago, College of Pharmacy, USA
Am J Manag Care 9:S103-14; quiz S115-20. 2003..Benefit-to-risk analyses will be necessary for determining how effective novel therapies will compare with established regimens... - YM-150, a Factor Xa inhibitor for the prevention of venous thromboembolism and coronary artery diseaseAnna Markel Vaysman
The University of Illinois at Chicago, Department of Pharmacy Practice, Antithrombosis Center and Center for Pharmacoeconomic Research, College of Pharmacy and Medical Center, 833 S Wood St, M C 886, Chicago, IL 60612, USA
Curr Opin Investig Drugs 11:333-9. 2010..The phase III trials would assess the efficacy of YM-150 in the prevention of VTE in a larger number of patients... - Rivaroxaban: an oral direct inhibitor of factor XaMichael P Gulseth
University of Minnesota College of Pharmacy, Duluth, MN 55812, USA
Am J Health Syst Pharm 65:1520-9. 2008..The mechanism of action, pharmacodynamics, pharmacokinetics, efficacy in clinical trials, interactions, adverse effects and toxicity, and place in therapy of rivaroxaban are reviewed... - Postdischarge oral versus injectable anticoagulation following major orthopedic surgeryAndrew F Shorr
Pulmonary and Critical Care, Washington Hospital Center, Georgetown University, Washington, DC 34685, USA
Ann Pharmacother 42:1222-8. 2008..Multiple clinical studies have shown postdischarge anticoagulation to be beneficial following major orthopedic surgery (MOS); however, outpatient prophylaxis is not widely practiced... - Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic settingAnn K Wittkowsky
School of Pharmacy, University of Washington, Seattle, WA, USA
Chest 130:1385-9. 2006..Telephone follow-up can be successfully used to manage warfarin therapy in patients who are unable to present in person to an anticoagulation clinic... - Factors influencing warfarin dose requirements in African-AmericansKathryn M Momary
Mercer University College of Pharmacy, 3001 Mercer University Dr, Atlanta, GA, 30341 4155, USA
Pharmacogenomics 8:1535-44. 2007.... - Uncertain times for oral anticoagulation therapyEdith A Nutescu
Am J Health Syst Pharm 62:1449. 2005 - Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparinSarah A Spinler
Cardiovascular Division, Department of Medicine, Philadelphia College of Pharmacy, University of Pennsylvania, Philadelphia, PA, USA
Ann Pharmacother 39:1275-85. 2005..To review the availability, mechanisms, limitations, and clinical application of point-of-care (POC) devices used in monitoring anticoagulation with unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs)... - Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitorsSarah A Spinler
Cardiovascular Division, Department of Medicine, Philadelphia College of Pharmacy, University of Pennsylvania, Philadelphia, PA 19104 4495, USA
Ann Pharmacother 39:1049-55. 2005..To review the availability, mechanisms, limitations, and clinical application of point-of-care (POC) devices used in the management of warfarin and parenteral direct thrombin inhibitors... - Barriers to patient self-testing of prothrombin time: national survey of anticoagulation practitionersAnn K Wittkowsky
School of Pharmacy, University of Washington, Seattle, Washington, USA
Pharmacotherapy 25:265-9. 2005..7%). Over 75% of respondents believed that some reimbursement for the cost of self-testing devices and supplies would increase the likelihood that anticoagulation clinics would recommend INR self-testing... - Current and emerging treatment options for venous thrombosis: a case discussionStuart T Haines
University of Maryland School of Pharmacy, Baltimore, MD, USA
Am J Health Syst Pharm 62:593-605. 2005 - Generic warfarin: implications for clinical practice and perceptions of anticoagulation providersRachel A Bongiorno
University of Maryland School of Pharmacy, Baltimore, Maryland, USA
Semin Thromb Hemost 30:619-26. 2004..These perceptions may change over time as additional data showing comparative therapeutic outcomes between generic and brand name formulations are published... - Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomesAdam J Duhl
Department of Obstetrics and Gynecology, Mercy Hospital of Pittsburgh, Pittsburgh, PA, USA
Am J Obstet Gynecol 197:457.e1-21. 2007.... - Ximelagatran: an oral direct thrombin inhibitorWilliam E Dager
Department of Pharmaceutical Services, University of California Davis Medical Center, Sacramento, CA, USA
Ann Pharmacother 38:1881-97. 2004.... - Shifting paradigms in oral anticoagulation managementEdith A Nutescu
J Cardiovasc Pharmacol Ther 9:149-50. 2004 - Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-AmericansHarumi Takahashi
Department of Pharmacotherapy, Meiji Pharmaceutical University, Kiyose, Tokyo, Japan
Pharmacogenet Genomics 16:101-10. 2006.... - Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation ForumDavid A Garcia
University of New Mexico School of Medicine, Albuquerque, NM, USA
Ann Pharmacother 42:979-88. 2008....